🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bydgoszcz
Clinical trial register · Poland

Clinical Trials in Bydgoszcz, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2681 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:47 UTC
2681
Studies in scope
all four open statuses
1400
Recruiting now
open to new participants
514
Lead sponsors
across recruiting studies
Top sites
Warsaw 1297 Krakow 869 Poznan 699 Gdansk 656 Lodz 622
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca49 Janssen Research & Development, LLC42 Merck Sharp & Dohme LLC38 Hoffmann-La Roche37 Eli Lilly and Company19
Site location
Warsaw1297 Krakow869 Poznan699 Gdansk656 Lodz622
All 261 locations
Target enrolment
to

Trials with a site in Bydgoszcz

533 of 2681 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Bialystok, Bydgoszcz, Katowice
2026-11-09
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
Bielsko-Biala, Bydgoszcz, Katowice, Krakow, Olsztyn, Poznan, Warsaw, Wałbrzych
2026-09-11
Not yet open
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
1,072
Bydgoszcz, Kielce, Krakow
2026-09-01
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463Obesity, Overweight, Chronic Weight Management
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Biała Podlaska, Bydgoszcz, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz
2026-08-31
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Biała Podlaska, Bydgoszcz, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz
2026-08-28
Recruiting
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
NCT07623174Metastatic Colorectal Cancer
Takeda
Observational
110
Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Opole, Przemyśl, Bialystok
2026-08-13
Recruiting
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841Overweight, Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 3
450
Bialystok, Bydgoszcz, Bygdoszcz, Lodz, Poznan, Staszów, Warsaw
2026-08-12
Not yet open
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Bialystok, Bielsko-Biala, Bydgoszcz, Gdansk, Krakow, Leszno, Lodz, Olkusz
2026-08
Recruiting
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
DrugApraglutide
VectivBio AG
Phase 3
124
Bydgoszcz, Lublin, Wroclaw
2026-08
Recruiting
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
NCT07348640Steno-occlusive Disease
DrugsGadopiclenol·Gadoterate meglumine
Guerbet
Phase 3
315
Bydgoszcz, Gdansk, Lublin
2026-07-28
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Bialystok, Bydgoszcz, Krakow, Poznan, Warsaw
2026-07-27
Recruiting
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
NCT06987539Generalized Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 2
15
Bydgoszcz, Katowice
2026-07-21
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Bialystok, Bydgoszcz, Kielce, Krakow, Lodz, Lublin, Poznan, Radom
2026-06-29
Recruiting
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
NCT07665723Active Ulcerative Colitis
DrugsDextromethorphan·Caffeine·Afimkibart·Omeprazole
Hoffmann-La Roche
Phase 1
25
Bydgoszcz, Lodz, Lublin, Nowy Targ, Pabianice, Późna, Warsaw, Wroc?aw
2026-06-29
Recruiting
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
NCT07154745Paroxysmal Nocturnal Hemoglobinuria
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
35
Bydgoszcz
2026-06-11
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
NCT07596849Graves Disease
DrugEfgartigimod PH20
argenx
Phase 3
230
Krakow, Katowice, Bydgoszcz, Zamość
2026-06-10
By invitation
The Use of Immersive Virtual Reality as a Method of Treating Anxiety and Procedural Pain During Endovenous Laser Ablation (EVLA) of Lower Varicose Veins Under Tumescent Anesthesia
NCT07624929Chronic Venous Insufficiency, CVI
Bydgoszcz University of Science and Technology
Not applicable
100
Bydgoszcz
2026-06-10
By invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Bydgoszcz, Poznan, Rzeszów, Sopot, Szczecin, Tychy, Warsaw, Wroclaw
2026-06-08
Recruiting
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
NCT07024706Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
DrugsAcalabrutinib·Venetoclax
AstraZeneca
Phase 2
80
Bydgoszcz, Krakow, Lodz, Lublin, Warsaw
2026-06-04
Recruiting
Prevention With Ismigen of RTIs in Kids
NCT07578012Respiratory Tract Infections (RTI), Healthy Children
Lallemand Pharma AG
Phase 4
224
Bialystok, Bydgoszcz, Krakow, Lublin, Oświęcim, Poznan, Tarnów
2026-06-01
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsJNJ-79635322·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Bydgoszcz, Gdansk, Katowice, Lublin, Warsaw, Wałbrzych
2026-05-31
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Bydgoszcz, Chojnice, Gdansk, Katowice, Kielce, Lublin, Piotrkow Trybunalski, Poznan
2026-05-28
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
Bydgoszcz, Krakow, Lublin, Rzeszów, Szczecin, Wroclaw, Zamość
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
Bydgoszcz, Krakow, Lublin, Rzeszów, Szczecin, Zamość
2026-05-22
Recruiting
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
NCT07554495Polyarticular Course Juvenile Idiopathic Arthritis
DrugFilgotinib
Alfasigma S.p.A.
Phase 3
65
Bydgoszcz, Torun, Warsaw
2026-05-21
Recruiting
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
NCT07501702Myasthenia Gravis, Generalized
DrugPovetacicept
Vertex Pharmaceuticals Incorporated
Phase 2
30
Bydgoszcz, Katowice, Poznan, Warsaw
2026-05-13
Recruiting
Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
NCT07370649Human Immunodeficiency Virus (HIV)-1 Infection, HIV-1 Subtype A6 Infection, HIV-1 Subtype B Infection, Virologically Suppressed HIV-1 Infection Receiving Long-Acting Antiretroviral Therapy
DrugCabotegravir
Pomeranian Medical University Szczecin
Observational
250
Szczecin, Bydgoszcz, Gdansk, Warsaw, Wroclaw
2026-05-12
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
DrugsRisankizumab·Guselkumab
Janssen Research & Development, LLC
Phase 3
530
Bydgoszcz, Krakow, Rzeszów, Szczecin, Torun, Warsaw
2026-04-21
Recruiting
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307Obesity, Overweight, Osteoarthritis, Knee
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
400
Bialystok, Bydgoszcz, Krakow, Warsaw
2026-04-20
Recruiting
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960Psoriatic Arthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
140
Bydgoszcz, Torun, Lublin, Warsaw
2026-04-20
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
DrugBI 3000202
Boehringer Ingelheim
Phase 2
405
Bydgoszcz, Krakow, Poznan, Warsaw, Wroclaw
2026-04-20
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT07287670Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics
Phase 2
85
Bydgoszcz, Nowa Sól, Warsaw
2026-04-16
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
245
Bydgoszcz, Częstochowa, Katowice, Krakow, Lodz, Lublin, Nadarzyn, Nowa Sól
2026-04-13
Recruiting
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07481630Obesity, Knee Osteoarthritis (OA)
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
400
Bialystok, Bydgoszcz, Krakow, Warsaw
2026-04-13
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT07540221CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugsGamunex-C·Xembify
Grifols Therapeutics LLC
Phase 3
40
Bydgoszcz, Katowice
2026-04-02
Recruiting
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
NCT07503873Multiple Sclerosis
DrugUblituximab
TG Therapeutics, Inc.
Phase 2
350
Bydgoszcz, Katowice, Kielce, Lodz, Poznan, Warsaw
2026-04-01
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Bydgoszcz, Krakow, Olsztyn
2026-03-27
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463Multiple Sclerosis (MS) Primary Progressive
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
705
Bydgoszcz, Zabrze, Katowice, Plewiska, Poznan, Gdansk, Lublin, Nowa Sól
2026-03-23
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019Secondary Progressive Multiple Sclerosis
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
990
Bydgoszcz, Nowa Sól, Rzeszów, Katowice, Poznan, Lublin, Szczecin, Lodz
2026-03-23
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Bialystok, Bydgoszcz, Dębica, Lublin, Pabianice, Poznan, Ruda Śląska, Siedlce
2026-03-23
Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms
DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab
Merck Sharp & Dohme LLC
Phase 3
450
Bydgoszcz
2026-03-23
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Bialystok, Bydgoszcz, Gdynia, Krakow, Lublin, Opole, Tarnów, Tychy
2026-03-16
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
Poznan, Rzeszw, Katowice, ?ory, ?ód?, Bydgoszcz, Gda?sk, Kielce
2026-03-10
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
DrugsIdelalisib·Pirtobrutinib
Eli Lilly and Company
Phase 4
150
Brzozów, Bydgoszcz, Katowice
2026-03-09
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
272
Bydgoszcz, Krakow
2026-03-09
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
Bydgoszcz, Bytom, Katowice, Krakow, Nadarzyn, Nowa Sól, Poznan, Płońsk
2026-03-05
Active, closed
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
DrugBerobenatide
Pfizer
Phase 3
1,078
Lodz, Bialystok, Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Katowice
2026-02-24
Recruiting
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
NCT07461220PARKINSON DISEASE (Disorder), Apathy, Safety
Integrative Research Laboratories AB
Phase 1/2
75
Bydgoszcz, Katowice, Lodz, Szczecin, Warsaw
2026-02-18
Active, closed
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Bydgoszcz, Lublin, Olsztyn, Tarnów, Warsaw
2026-02-16
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
Bydgoszcz, Gdansk
2026-02-11
Recruiting
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
NCT07340320Type II Diabetes Mellitus
DrugCX11
Corxel Pharmaceuticals
Phase 2
240
Poznan, Bydgoszcz, Krakow, Tarnów, Wroclaw, Lodz, Warsaw, Gdansk
2026-02-06
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003Amyotrophic Lateral Sclerosis
DrugPridopidine
Prilenia
Phase 3
500
Bydgoszcz, Krakow, Warsaw
2026-02-01
By invitation
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
NCT07286006Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
372
Bydgoszcz
2026-01-26
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288Idiopathic Pulmonary Fibrosis
AbbVie
Phase 2
165
Bydgoszcz
2026-01-23
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184944Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
751
Bydgoszcz, Kłodzko, Lublin, Staszów, Szczecin, Warsaw
2026-01-22
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
751
Bydgoszcz, Katowice, Lublin, Szczecin, Torun
2026-01-16
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Bialystok, Bydgoszcz, Elblag, Krakow, Lublin, Nadarzyn, Olsztyn, Torun
2026-01-15
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901Obesity With Diabetes, Overweight With Diabetes
DrugRibupatide
Kailera
Phase 3
1,156
Bydgoszcz, Torun, Krakow, Lublin, Siedlce, Warsaw, Bialystok, Gdynia
2026-01-12
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459Idiopathic Pulmonary Fibrosis
Contineum Therapeutics
Phase 2
324
Bydgoszcz, Bialystok
2026-01-08
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsBMS-986504·Nab-paclitaxel·Pemetrexed·Paclitaxel
Bristol-Myers Squibb
Phase 2/3
590
Poznan, Krakow, Jelenia Góra, Warsaw, Wieliszew, Prabuty, Bydgoszcz
2026-01-02
By invitation
Comparison Between Velys J&J Robotic-assisted and Cori S&N Robotic-assisted Total Knee Arthroplasty
NCT07555067Knee Arthritis Osteoarthritis
Jan Biziel University Hospital No 2 in Bydgoszcz
Observational
200
Bydgoszcz
2026-01-01
Not yet open
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
NCT07203846ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota, Platelet Aggregation
DrugRifaximin
Collegium Medicum w Bydgoszczy
Phase 4
50
Bydgoszcz
2026-01-01
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979Obesity
DrugsRibupatide·Semaglutide
Kailera
Phase 3
1,200
Krakow, Warsaw, Gdynia, Chorzów, Bydgoszcz, Wroclaw, Kielce
2025-12-30
Recruiting
TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
NCT07668869Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastoma Multiforme, Adult
Prof. Franciszek Lukaszczyk Memorial Oncology Center
Not applicable
92
Bydgoszcz
2025-12-30
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT07294170Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis
DrugsEmpasiprubart·Efgartigimod
argenx
Observational
70
Bydgoszcz, Krakow, Katowice, Warsaw
2025-12-19
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Bialystok, Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Katowice, Krakow
2025-12-19
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
DrugsEmpasiprubart·Efgartigimod
argenx
Phase 2
70
Bydgoszcz, Katowice, Warsaw
2025-12-19
Active, closed
Results Between Robotic-assisted and Manual Total Knee Arthroplasty With Kinematic Alignment
NCT07452809Knee Arthritis, Osteoarthritis
Jakub Błaszczyk
Not applicable
100
Bydgoszcz
2025-12-17
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Ruda Śląska, Zabrze
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Bydgoszcz, Koszalin, Krakow, Skórzewo, Sosnowiec, Warsaw, Wrocaw
2025-12-12
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Bialystok, Bydgoszcz, Gdansk, Warsaw
2025-12-10
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Poznan, Bydgoszcz, Chorzów, Katowice, Krakow, Lublin, Sochaczew, Wroclaw
2025-12-02
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Radom, Ruda Śląska
2025-12-01
Recruiting
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542Neovascular Age-related Macular Degeneration
DrugRanibizumab
Hoffmann-La Roche
Phase 3
250
Krakow, Bielsko-Biala, Bydgoszcz, Gliwice, Lódz, Lublin, Olsztyn
2025-11-27
Recruiting
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625Acromegaly
Debiopharm International SA
Phase 3
119
Bydgoszcz, Gliwice, Krakow, Poznan, Wroclaw
2025-11-26
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan·Cabozantinib
Merck Sharp & Dohme LLC
Phase 3
904
Skórzewo, Bydgoszcz, Krakow, Siedlce, Warsaw, Przemyśl, Koszalin
2025-11-26
Recruiting
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
NCT07195149Chronic Coronary Syndrome, Stable Coronary Artery Disease CAD
DrugsPrasugrel·Aspirin
Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.
Phase 3
1,703
Bialystok, Bydgoszcz, Gdansk, Grudziądz, Katowice, Krakow, Lodz, Nowa Sól
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Bia?ystok, Bydgoszcz, Gda?sk, Katowice, Krakow, Lublin, Oświęcim, Rzeszów
2025-11-24
Active, closed
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886Multiple Sclerosis
Hoffmann-La Roche
Phase 2
193
?ory, Bydgoszcz, Lodz, Rzeszów, Zabrze
2025-11-13
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Krakow, Bydgoszcz, Chojnice, Katowice, Lodz, Lublin, Rzeszów, Skorzewo
2025-11-11
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
Lublin, Bydgoszcz
2025-11-05
Recruiting
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
NCT07231939Coronary Artery Disease, Acute Kidney Injury, Contrast-Induced Acute Kidney Injury, Percutaneous Coronary Intervention
DrugDapagliflozin
Collegium Medicum w Bydgoszczy
Observational
4,000
Bydgoszcz
2025-11-01
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Bydgoszcz, Elblag, Grudziądz, Komorniki, Leszno, Puławy, Wroclaw
2025-10-31
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Bydgoszcz, Gdansk, Krakow, Lodz, Olsztyn
2025-10-28
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Bydgoszcz, Katowice, Lublin, Warsaw
2025-10-27
Recruiting
Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
NCT07267949Atrial Fibrillation (AF)
Acesion Pharma
Phase 2
200
Bydgoszcz, Chrzanów, Dąbrowa Górnicza, Katowice, Szczecin, Tychy
2025-10-22
Recruiting
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
NCT07260669Endometriosis
Gesynta Pharma AB
Phase 2
190
Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Siedlce, Skorzewo, Szczecin
2025-10-15
Recruiting
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
NCT07156175Microscopic Colitis
Sanofi
Phase 2
54
Bydgoszcz, Warsaw
2025-10-14
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
DrugsTulisokibart·Methotrexate
Merck Sharp & Dohme LLC
Phase 2
185
Bydgoszcz, Torun, Lublin, Warsaw, Bytom
2025-10-08
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Bydgoszcz, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan, Rzeszów
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Bydgoszcz, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Bydgoszcz, Elblag, Katowice, Krakow, Kłodzko, Lodz, Lublin, Nowy Targ
2025-10-01
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Bydgoszcz, Skórzewo, Szczecin, Warsaw, Wroclaw
2025-09-30
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Bydgoszcz, Chojnice, Katowice, Knurów, Nowy Targ, Poznan, Skierniewice, Szczecin
2025-09-29
Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417Ulcerative Colitis
DrugFilgotinib
Alfasigma S.p.A.
Phase 3
80
Bydgoszcz, Lodz, Rzeszów, Warsaw
2025-09-29
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Bydgoszcz, Torun, Lublin, Warsaw
2025-09-26
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
DrugZilebesiran
Alnylam Pharmaceuticals
Phase 3
11,000
Bydgoszcz, Chojnice, Chorzów, Chrzanów, Częstochowa, Dębica, Gdansk, Gdynia
2025-09-22
Active, closed
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,101
Bydgoszcz, Katowice, Krakow, Lublin, Rzeszów, Warsaw, Wroc?aw, Zabrze
2025-09-17
Active, closed
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
NCT07037875GERD (Gastroesophageal Reflux Disease)
DrugsLinaprazan glurate·Lansoprazole
Cinclus Pharma Holding AB
Phase 3
500
Bialystok, Bydgoszcz, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Lodz
2025-09-11
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
Bialystok, Bydgoszcz, Koszalin, Warsaw
2025-09-02
Rows per page Showing 1–100 of 533
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-poland/city/bydgoszcz

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,681 studies in total at the last sync on 26 Sep 2026, 19:47 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 533 of those studies with a site in Bydgoszcz.

How many clinical trials are recruiting in Bydgoszcz?

247 of the 533 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:47 UTC sync. A further 4 have not yet opened recruitment, 267 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bydgoszcz), 533 studies
PhaseStudiesRecruitingShare
Phase 336615368.7%
Phase 21025219.1%
Observational17113.2%
Not applicable12102.3%
Phase 2/31172.1%
Phase 1/21041.9%
Phase 4851.5%
Phase 1751.3%

Most active sponsors

Lead sponsors with the most studies (Bydgoszcz)
Lead sponsorStudiesRecruiting
AstraZeneca4914
Janssen Research & Development, LLC4217
Merck Sharp & Dohme LLC3818
Hoffmann-La Roche3713
Eli Lilly and Company198
Bristol-Myers Squibb187
Novartis Pharmaceuticals186
AbbVie157
argenx116
Sanofi116
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.